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Abstract
In the present study, liquid chromatography coupled to an Orbitrap mass spectrometer (HPLC–Q-Orbitrap MS) was used as 
an approach for identification and quantification of 113 drugs simultaneously in biological samples (whole blood/plasma/
serum). Samples were prepared using liquid–liquid extraction conducted using a trizma/isopropanol/butyl chloride buffer 
system. Reversed-phase separation employing a column (50 × 2.1 mm) packed with 2.6-μm C18 particles was then performed 
under gradient elution with mobile phase composition consisting of acetic acid and aqueous-acetonitrile mixtures with the 
acetonitrile content ranging from 10 to 100% v/v. Compounds were detected with high-resolution MS operated in full scan 
mode having a mass accuracy < 5 ppm. In this study, isobaric compounds (same nominal mass) were easily distinguished and 
identified by their different retention times. Extracted ion chromatograms (XICs) with narrow mass tolerance window (5 ppm) 
provided analysis with acceptable linearity (r2) ranged from 0.9530 to 1, low limits of detection (LOD) (0.02–39 ng mL−1) 
and low limit of quantification (LOQ) (0.1–130 ng mL−1). The developed method was applied to successfully analyse drugs 
in 26 blood samples from positive forensic cases and proved that this technique was able to detect analytes at trace level.
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Introduction
Simultaneous screening of a broad range of drugs (here 
simultaneous is intended to mean in one sample, using a 
single analytical separation method) is essential in a foren-
sic analysis environment. The analysis should rapidly and 
reliably identify target or important non-target analytes in 
biological samples on a routine basis. However, deficiencies 
may exist in particular methods that are required to provide 
routine analysis of biological samples, especially when the 
complexity of the samples presents difficulty in detection 
selectivity (i.e., the ability to adequately identify a specific 
drug), and when compounds cannot be detected at a suf-
ficiently low amount.
Numerous analytical techniques have been employed in 
forensic laboratories to comprehensively analyse a broad 
range of drugs in complex samples, usually based on the sep-
aration techniques gas chromatography–mass spectrometry 
(GC–MS) [1] and liquid chromatography–mass spectrom-
etry (LC–MS), although direct MS analysis approaches have 
also been proposed, where the sample is analysed directly 
by the use of MS without prior chromatographic separation 
[2, 3]. GC–MS has proven to be a reliable technique for 
drug analysis because of its high selectivity, sensitivity and 
the possibility of positive identification provided by drug 
MS libraries. However, low volatility or thermal stability 
of some drug substances and/or the need to perform deri-
vatisation steps are method limitations [4]. LC–MS is one 
of the most important techniques for routine screening of 
substances in biological samples because of its anticipated 
sensitivity, potential detection specificity provided by appro-
priate MS strategies, and its suitability toward molecules of 
variable polarity, molecular mass and thermal stability [5]. 
Therefore, it enjoys the position of being a preferred analyti-
cal tool for screening and identifying drugs in clinical and 
forensic toxicology [6].
Contemporary studies are often conducted using LC 
coupled with tandem mass spectrometry (LC–MS/MS) for 
drug screening and identification in biological samples [7, 
8]. There are some drawbacks to LC–MS/MS due to (i) the 
many transitions (for quantification and qualification ions) 
which must be selected for multi-component samples, espe-
cially when employing fast chromatographic analysis, reduc-
ing the sensitivity or comprehensiveness of the method, and 
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(ii) the technique does not allow identification of unknown 
molecules, since this is necessarily a targeted method, and 
ions for known compounds will need to be selected—con-
ceptually a difficult task [9]. More recently, considerable 
interest from the analytical and forensic toxicology area has 
focused on high-resolution MS (HRMS) techniques [10]. 
Selectivity for HRMS combines both mass resolution and 
mass accuracy considerations. In addition, HRMS instru-
ments such as time of flight (TOF) and Orbitrap MS [11, 
12] offer various advantages for drug screening and iden-
tification. For routine operations, they provide resolutions 
between 40,000 and 100,000 full width at half maximum 
(FWHM), or even higher for some Orbitrap MS instruments. 
These techniques offer the possibility of increasing the num-
ber of compounds which can be analysed in a given time, 
and importantly allow for retrospective data searching to 
investigate unknown or unexpected compounds present in 
the samples, for instance as a result of the emergence of 
designer drugs. In fact, based on the previous study, LC–Q-
TOFMS technique allows the identification via library 
search based on accurate mass fragment spectra of all essen-
tial components in a single run using the “Auto-MS–MS 
mode” [13]. Several studies report using HRMS techniques 
to identify drug compounds in various samples [14–17].
The Orbitrap HRMS mass analyser was first described in 
2000 by Makarov [18]. The Exactive-Orbitrap MS (Orbitrap 
MS) provides high selectivity and sensitivity for the iden-
tification and quantification of drug compounds; thus, this 
analyser allows selective detection of compounds in complex 
samples such as in biological [19–21] and in water samples 
[22]. The Q-Exactive is a hybrid arrangement of the Orbitrap 
MS, coupling the high resolving Orbitrap sector with the 
added selectivity of a quadrupole unit mass resolution sector 
[23]. The Q-Exactive permits identification, confirmation 
and quantification with high confidence in a single analysis, 
with up to 100,000 FWHM mass resolution, to improve the 
sensitivity and selectivity of the method [24]. It allows non-
target screening in a full scan mode with targeted MS/MS 
analysis in a single analysis, or it may operate separately 
[25]. High-resolution full scan (FS) mode, in which all ions 
are detected and analysed by the mass spectrometer, is the 
standard method used [26]. Full scan HRMS is adequate 
to achieve chemical specificity and acquire qualitative and 
quantitative data for many chemical substances [27].
The purpose of the present study was to develop a 
HPLC–Q-Orbitrap MS method for the simultaneous screen-
ing and identification of a broad range of drugs, and then to 
apply this method to blood samples. This method permits 
the simultaneous identification and confirmation of a broad 
range of drugs in a single analysis with full scan mode, 
which proves to be suitable for a wider range of compounds. 
An exact mass database including the accurate mass and 
retention time for each drug was developed using the results 
of the HRMS measurements, with a heated electrospray ioni-
sation (HESI) source in positive ion mode. The proposed 
method was applied to the analysis of 26 biological samples 
(mainly whole blood, but some serum and plasma) from 
forensic cases.
Experimental
Reagents and Materials
Acetonitrile (HPLC grade) was purchased from Biolab Sci-
entific Pty Ltd. (Mulgrave, Australia). Water was distilled 
and deionised with a Milli-Q system (Merck Millipore, Bed-
ford, MA). Acetic acid (100% v/v) was obtained from BDH 
Chemicals Australia Pty Ltd (Merck). A standard mixture 
of drugs containing 113 drugs was prepared by the Victo-
rian Institute of Forensic Medicine (VIFM) with variable 
concentrations of each drug (refer to Table 1). The standard 
mixture was stored at 4 °C before analysis.
Extraction Procedure
A total of 26 forensic cases (blood/plasma/serum) obtained 
from VIFM were labelled by numbers from 1 to 26. The 
samples consisted of 22 postmortem cases (case no. 1–8, 
10–21, 23, 26) and 4 antemortem cases (case no. 9, 22, 24, 
25). For the extraction procedure, the samples were prepared 
and extracted using the routine method used by the VIFM in 
their casework. Briefly, liquid–liquid extraction (LLE) with 
100-μL Trizma buffer (pH 9) was added to 100 μL of the 
sample. Then, 1 mL of 10% isopropanol/butyl chloride was 
added to the buffer and the organic phase was transferred 
to autosampler vials following a brief centrifugation. The 
organic phase was evaporated using nitrogen. Finally, the 
extracts were reconstituted in 50 μL 0.1% of formic acid in 
acetonitrile and 450 μL of 50 mmol ammonium formate in 
water at a pH of 3.5.
Instrumentation
Standards and samples were analysed by ultra-high perfor-
mance liquid chromatography (UHPLC) in combination 
with a Q-Exactive Plus Orbitrap mass spectrometer (Thermo 
Fisher Scientific, Scoresby, Australia) which was equipped 
with a heated electrospray ionisation source (HESI), binary 
pump, and autosampler. The HESI source was operated in 
positive ion mode for the ionisation of target compounds. 
Chromatographic separations were performed on a Thermo 
Accucore C18 phase column (50 × 2.1 mm) with 2.6-μm par-
ticle size. Thus, although the HPLC instrument was capa-
ble of ultra-high resolution (UHPLC) due to pump pres-
sure capability, the 2.6-μm particle size does not correlate 
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Table 1  Characteristics of targeted 113 drugs with linearity based on calibration range, LODs and LOQs obtained by the full scan mode Orbit-
rap MS, in ng mL−1
No. Compounds Exact mass 
[M + H]+
Accurate 
mass 
[M + H]+
Mass 
accuracy 
(ppm)
Ret. time 
(min)
Calib. range 
(ng mL−1)
Linearity LOD 
(ng mL−1)
LOQ (ng mL−1)
1 6-Acetylmor-
phine
328.1549 328.1540 2.7 1.18 1–600 0.9947 0.3 1.0
2 7-Amino-clon-
azepam
286.0747 286.0739 2.8 3.44 10–600 0.9959 3.0 10
3 7-Amino-fluni-
trazepam
284.1199 284.1190 3.2 4.70 1–130 0.9983 0.3 1.0
4 7-Amino-
nitrazepam
252.1137 252.1130 2.8 1.19 1–600 0.9963 0.3 1.0
5 Alprazolam 309.0907 309.0898 2.9 7.68 1–130 0.9996 0.3 1.0
6 Amisulpride 370.1801 370.1790 2.9 1.57 10–600 0.9926 3.0 10
7 Amphetamine 136.1126 136.1120 4.4 1.06 0.5–600 0.9982 0.2 0.5
8 Aripiprazole 448.1559 448.1552 1.6 7.30 1–600 0.9999 0.3 1.0
9 Benzhexol 302.2484 302.2474 3.3 6.80 0.5–600 0.9931 0.2 0.5
10 Benzoylecgo-
nine
290.1393 290.1384 3.1 2.27 10–600 0.9972 3.0 10
11 Benztropine 308.2014 308.2005 2.9 7.33 0.5–600 0.9992 0.2 0.5
12 Bromazepam 316.0086 316.0077 2.9 6.16 0.5–600 0.9999 0.2 0.5
13 Bromperidol 420.0975 420.0969 1.4 6.72 8–30 0.9966 2.4 8.0
14 Bupivacaine 289.2280 289.2271 3.1 5.01 1.25–2000 0.9965 0.4 1.3
15 Bupropion 240.1155 240.1149 2.5 4.71 0.5–600 0.9967 0.2 0.5
16 Buspirone 386.2556 386.2547 2.3 5.43 0.1–30 0.9966 0.03 0.1
17 Caffeine 195.0882 195.0876 3.1 1.25 50–33,000 0.9984 15 50
18 Carbamaz-
epine
237.1028 237.1020 3.4 6.88 50–33,000 0.9975 15 50
19 Chlorphena-
mine
275.1315 275.1304 4.0 5.17 0.05–130 0.9912 0.02 0.1
20 Chlorproma-
zine
319.1036 319.1027 2.8 7.59 0.5–600 0.9995 0.2 0.5
21 Chlorprothix-
ene
316.0927 316.0918 2.9 7.74 0.5–600 0.9994 0.2 0.5
22 Citalopram 325.1716 325.1707 2.8 6.29 0.5–600 0.9973 0.2 0.5
23 Clomipramine 315.1628 315.1619 2.9 7.86 0.5–600 0.9996 0.2 0.5
24 Clonazepam 316.0489 316.0480 2.9 7.65 0.5–600 0.9992 0.2 0.5
25 Clozapine 327.1377 327.1368 2.8 5.79 1.25––2000 0.9940 0.4 1.3
26 Cocaethylene 318.1706 318.1695 3.5 5.24 0.5–600 0.9952 0.2 0.5
27 Cocaine 304.1549 304.1540 2.9 4.14 0.5–600 0.9916 0.2 0.5
28 Colchicine 400.1760 400.1751 2.3 5.95 0.5–600 0.9985 0.2 0.5
29 Cotinine 177.1028 177.1021 3.9 0.64 0.5–600 0.9944 0.2 0.5
30 Desipramine 267.1861 267.1852 3.4 6.86 1–130 1.0000 0.3 1.0
31 Desmethylven-
lafaxine
264.1963 264.1954 3.4 2.62 0.5–600 0.9926 0.2 0.5
32 Diazepam 285.0795 285.0786 3.2 9.04 1.25–2000 0.9993 0.4 1.3
33 Diltiazem 415.1691 415.1683 1.9 6.50 1–130 0.9998 0.3 1.0
34 Diphenhy-
dramine
256.1701 256.1692 3.5 6.02 1.25–2000 0.9965 0.4 1.3
35 Disopyramide 340.2389 340.2380 2.7 4.21 5–13,000 0.9936 1.5 5.0
36 Dothiepin 296.1473 296.1463 3.4 6.87 0.5–600 0.9994 0.2 0.5
37 Doxepin 280.1701 280.1692 3.2 6.33 0.5–600 0.9935 0.2 0.5
38 Doxylamine 271.1811 271.1801 3.7 2.09 10–600 0.9908 3.0 10
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Table 1  (continued)
No. Compounds Exact mass 
[M + H]+
Accurate 
mass 
[M + H]+
Mass 
accuracy 
(ppm)
Ret. time 
(min)
Calib. range 
(ng mL−1)
Linearity LOD 
(ng mL−1)
LOQ (ng mL−1)
39 Droperidol 380.1774 380.1766 2.1 5.80 1–130 1.0000 0.3 1.0
40 Duloxetine 298.1266 298.1257 3.0 7.13 1–600 0.9998 0.3 1.0
41 Ecgonine 
methyl ester
200.1287 200.1281 3.0 0.58 0.5–600 0.9986 0.2 0.5
42 Ephedrine 166.1232 166.1225 4.2 0.89 0.5–600 0.9989 0.2 0.5
43 Fenfluramine 232.1313 232.1305 3.5 5.16 0.5–600 0.9989 0.2 0.5
44 Flunitrazepam 314.0941 314.0932 2.9 8.04 0.1–130 0.9997 0.03 0.1
45 Fluoxetine 310.1419 310.1410 2.9 7.52 0.5–600 1.0000 0.2 0.5
46 Fluphenazine 438.1827 438.1819 1.8 8.10 0.1–30 0.9946 0.03 0.1
47 Flurazepam 388.1592 388.1590 0.5 5.91 0.1–30 0.9999 0.03 0.1
48 Fluspirilene 476.2513 476.2508 1.1 8.86 8–30 1.0000 2.4 8.0
49 Fluvoxamine 319.1633 319.1624 2.8 6.99 0.5–600 1.0000 0.2 0.5
50 Haloperidol 376.1479 376.1461 4.8 6.54 1–130 0.9998 0.3 1.0
51 Hydroxyrisp-
eridone
427.2146 427.2138 1.9 4.9 0.05–130 0.9938 0.02 0.1
52 Imipramine 281.2018 281.2009 3.2 6.96 0.5–600 0.9990 0.2 0.5
53 Ketamine 238.0999 238.0991 3.4 1.68 5–13,000 0.9974 1.5 5.0
54 Levetiracetam 171.1134 171.1126 4.7 0.91 50–33,000 0.9928 15 50
55 Levomeproma-
zine
329.1688 329.1679 2.7 7.25 0.5–600 0.9980 0.2 0.5
56 Lidocaine 235.1811 235.1802 3.8 1.44 5–13,000 0.9948 1.5 5.0
57 Lorazepam 321.0198 321.0187 3.4 7.59 0.1–130 0.9990 0.03 0.1
58 Loxapine 328.1217 328.1208 2.7 6.55 1–130 0.9987 0.3 1.0
59 MDAa 180.1025 180.1017 4.4 1.17 0.5–600 0.9988 0.2 0.5
60 MDMAb 194.1181 194.1177 2.1 1.30 0.05–130 0.9900 0.02 0.1
61 Mephedrone 178.1232 178.1225 3.9 1.39 0.5–600 0.9942 0.2 0.5
62 Methadone 310.2171 310.2162 2.9 7.20 0.5–600 0.9972 0.2 0.5
63 Metoclopra-
mide
300.1479 300.1471 2.7 2.26 0.5–600 0.9962 0.2 0.5
64 Mianserin 265.1705 265.1697 3.0 6.19 0.1–130 0.9989 0.03 0.1
65 Midazolam 326.0860 326.0852 2.5 5.97 0.5–600 0.9968 0.2 0.5
66 Mirtazepine 266.1657 266.1649 3.0 3.98 1–600 0.9952 0.3 1.0
67 Moclobemide 269.1057 269.1047 3.7 1.59 5–13,000 0.9968 1.5 5.0
68 Modafanil 274.0902 274.0893 3.3 6.22 130–600 1.0000 39 130
69 Nicotine 163.1235 163.1228 4.3 0.61 0.05–130 0.9944 0.02 0.1
70 Nifedipine 347.1244 347.1235 2.6 8.84 10–600 0.9936 3 10
71 Nitrazepam 282.0879 282.0871 2.8 7.29 0.1–130 0.9982 0.03 0.1
72 Nordiazepam 271.0638 271.0630 2.9 8.03 1.25–2000 0.9982 0.4 1.3
73 Nortriptyline 264.1752 264.1743 3.4 7.05 0.05–130 0.9994 0.02 0.1
74 Olanzapine 313.1487 313.1477 3.2 1.03 30–130 1.0000 9.0 30
75 Oxazepam 287.0587 287.0580 2.4 7.33 1.25–2000 0.9990 0.4 1.3
76 Oxprenolol 266.1756 266.1748 3.0 4.82 0.5–600 0.9960 0.2 0.5
77 Oxycodone 316.1549 316.1540 2.9 1.11 0.5–600 0.9938 0.2 0.5
78 Paracetamol 152.0712 152.0705 4.6 0.86 50–33,000 0.9935 15 50
79 Paroxetine 330.1506 330.1497 2.7 6.87 1–130 0.9952 0.3 1.0
80 Perazine 340.1847 340.1838 2.7 6.86 1–600 0.9961 0.3 1.0
81 Pericyazine 366.1640 366.1633 1.9 6.63 1–130 0.9989 0.3 1.0
82 Perphenazine 404.1563 404.1556 1.7 7.51 8–30 1.0000 2.4 8.0
83 Pethidine 248.1651 248.1642 3.6 4.38 1.25–2000 0.9910 0.4 1.3
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with conditions that define UHPLC, such as a particle 
size < 2.0 μm. Subsequently, the system will be referred to 
as LC. Samples were separated at 25 °C. 0.1% v/v acetic acid 
in water and acetonitrile were used as mobile phases A and 
B, respectively. Gradient elution started at 10% v/v of mobile 
phase B for 2 min, then linearly increased to 27% v/v B at 
5 min, then 27–50% v/v B at 10 min and from 50–100% v/v 
B at 14 min. The mobile phase content was held at 100% v/v 
B for 1 min and then decreased to 10% v/v B. The column 
was equilibrated at 10% v/v B for 4 min; the total analysis 
turnaround time was 20 min. The flow rate was 0.30 mL/
min, with injection volume of 15 μL.
The MS conditions were as follows: the sheath gas 
flow was set at 35, and the auxillary gas unit flow at 10 
(both arbitrary units), with a spray voltage of 3.0 kV. Cap-
illary and auxillary gas heater temperatures were set to 
320 and 300 °C, respectively. Full scan MS analysis (m/z 
50–600) was performed with resolution (70,000 FWHM), 
AGC target (1 × 106) and maximum IT (200 ms). The 
Orbitrap was calibrated daily by direct injection of the 
calibration solution in both positive and negative modes. 
Detection of analytes in samples was based on calculated 
exact mass and retention time of standard compounds, 
presented in Table 1. The mass tolerance window was set 
to 5 ppm for the analysis of each compound.
Table 1  (continued)
No. Compounds Exact mass 
[M + H]+
Accurate 
mass 
[M + H]+
Mass 
accuracy 
(ppm)
Ret. time 
(min)
Calib. range 
(ng mL−1)
Linearity LOD 
(ng mL−1)
LOQ (ng mL−1)
84 Phencyclidine 244.2065 244.2057 3.3 5.29 1.25–2000 0.9949 0.4 1.3
85 Pheniramine 241.1705 241.1696 3.7 2.02 1–600 0.9916 0.3 1.0
86 Pholcodine 399.2284 399.2276 2.0 0.60 1–130 0.9991 0.3 1.0
87 Pimozide 462.2357 462.2350 1.5 8.41 1–130 1.0000 0.3 1.0
88 Pipamperone 376.2400 376.2390 2.7 2.41 1–600 0.9917 0.3 1.0
89 Propoxyphene 340.2277 340.2268 2.7 7.11 1.25–2000 0.9975 0.4 1.3
90 Propranolol 260.1651 260.1642 3.5 5.66 0.5–600 0.9983 0.2 0.5
91 Quetiapine 384.1746 384.1737 2.3 6.07 0.5–600 0.9996 0.2 0.5
92 Quinine 325.1916 325.1907 2.8 2.76 50–33,000 0.9947 15 50
93 Reboxetine 314.1756 314.1747 2.9 6.32 0.5–600 0.9996 0.2 0.5
94 Risperidone 411.2196 411.2187 2.2 5.31 1–130 0.9978 0.3 1.0
95 Ropivacaine 275.2124 275.2115 3.3 3.80 0.5–600 0.9985 0.2 0.5
96 Sertraline 306.0816 306.0807 2.9 7.61 0.5–600 0.9998 0.2 0.5
97 Sildenafil 475.2128 475.2119 1.9 6.29 1–600 0.9998 0.3 1.0
98 Sotalol 273.1273 273.1264 3.3 0.75 10–600 0.9984 3.0 10
99 Strychnine 335.1759 335.1749 2.9 1.52 1.25–2000 0.9932 0.4 1.3
100 Sulpiride 342.1488 342.1478 2.9 0.79 0.5–600 0.9956 0.2 0.5
101 Thioridazine 371.1616 371.1607 2.4 8.31 1.25–2000 0.9964 0.4 1.3
102 Timolol 317.1648 317.1638 3.2 2.56 0.5–600 0.9998 0.2 0.5
103 Tramadol 264.1964 264.1955 3.4 2.02 1.25–2000 0.9904 0.4 1.3
104 Triazolam 343.0517 343.0507 2.9 7.85 1–130 0.9998 0.3 1.0
105 Trifluoperazine 408.1721 408.1713 1.9 8.48 1–130 0.9965 0.3 1.0
106 Trifluproma-
zine
353.1299 353.1291 2.3 8.17 0.5–600 0.9995 0.2 0.5
107 Venlafaxine 278.2120 278.2112 2.9 4.96 1.25–2000 0.9922 0.4 1.3
108 Verapamil 455.2910 455.2901 1.9 7.18 1–600 0.9997 0.3 1.0
109 Ziprasidone 413.1203 413.1194 2.2 6.11 1–130 0.9982 0.3 1.0
110 Zolpidem 308.1763 308.1754 2.9 4.77 0.5–600 0.9923 0.2 0.5
111 Zopiclone 389.1129 389.1117 3.1 2.96 0.05–130 0.9943 0.02 0.1
112 Zotepine 332.0876 332.0867 2.7 7.80 1–130 0.9998 0.3 1.0
113 Zuclopenthixol 401.1454 401.1447 1.8 7.75 0.05–130 0.9923 0.02 0.1
a 3,4-Methylenedioxyamphetamine
b 3,4-Methylenedioxymethamphetamine
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Data Analysis
For data evaluation, Xcalibur 3.0.63 (Thermo Fisher Sci-
entific) software was used to control the instrument and for 
data processing. TraceFinder 3.0 software (Thermo Fisher 
Scientific) was utilised for confirmation and quantification 
analysis with Microsoft Excel 2010.
Results and Discussion
LC‑Orbitrap MS
Although use of a monolith sorbent has the advantage of 
higher flow rates with reduced backpressures compared to 
conventional packed bed columns [28], here a C18 column 
(50 × 2.1 mm) with 2.6-μm particle size was installed in the 
LC system as the analytical column. Simultaneous detec-
tion of all analytes in one analysis was performed using 
the Orbitrap MS operated in full scan mode, with positive 
ionisation mode; in some cases, simultaneous detection 
arises for unresolved analytes. Each chromatographic run 
was completed within a total cycle time of 20 min (includ-
ing column re-equilibration). Acceptable chromatographic 
resolution or detection based on unique mass measurements 
was achieved, where all targeted peaks were eluted in less 
than 12 min (Fig. 1). Peak width at half peak height for a 
representative analyte was approximately 4.5 s, and peak 
capacity (nc) of the column under the conditions used here 
was approximately 70 (implying the column can resolve to 
baseline a maximum of 70 compounds). Since the refer-
ence standard comprised 113 drugs, considerable overlap 
of chromatographic peaks is anticipated, even on a pure 
statistical basis. The high mass resolving power provided 
by this technique is crucial in mass-domain separation of 
overlapping or closely adjacent peaks, and in ensuring that 
only one specific ion for each analyte contributes to the 
measurement. It is particularly useful when handling com-
plex samples such as biological samples [21]. In this study, 
70,000 FWHM was selected for the mass resolution, which 
achieved a satisfactory number of points per chromato-
graphic peak [28].
The increasing demand for analysis of many classes of 
drugs in a single chromatographic analysis using full scan 
accurate mass techniques (e.g., TOFMS and Orbitrap MS) 
supports high throughput analysis [11, 12]. Here, a full 
scan with a mass tolerance window of 5 ppm was used. The 
resulting total ion chromatogram (TIC) is shown in Fig. 1. 
Subsequently, target ions can be presented using extracted 
ion chromatogram (XIC) plots. Good peak shapes of each 
analyte were attained with a mass resolution of 70,000 
FWHM within 5 ppm mass accuracy of the protonated 
exact mass [M + H]+. The retention time for each analyte 
was estimated from triplicate analysis at one concentra-
tion level. Although the chromatographic result in Fig. 1 
might appear to exhibit broad peaks, this is a consequence 
of multiple peak overlaps due to relatively low total peak 
capacity. The use of extracted ion presentations for indi-
vidual compounds illustrates that they all have good narrow 
peak responses.
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Identification and Detection of Target Compounds
The screening of the 113 targeted component was per-
formed at full scan, with each compound identified using 
the accurate mass measurements of the [M + H]+ ion, with 
evaluation of the retention time. A retention time window 
of ± 0.2 min was applied for all analytes as determined from 
triplicate injections. Table 1 indicates the list of target drug 
compounds and their retention times, including exact mass 
for the given molecular formula (calculated mass from the 
molecular formula with appropriate number of decimal 
places), accurate mass (experimental mass that obtained 
from the actual measurement using the HRMS method), and 
mass accuracy for each compound.
Confirmation of 113 analytes was based on the mass 
accuracy operated at full scan (± 2.5 ppm) and provides 
method selectivity, with little interference, as shown in 
Fig. 2, for citalopram at tR 6.29 min, with an accurate mass 
of m/z 325.1716 and good peak shape. Table 1 demonstrates 
an excellent mass accuracy from − 2.9 to 4.8 ppm, which 
will reduce the probability of false positives.
High resolution specificity was capable of successfully 
differentiating 13 sets of nominally isobaric compounds 
(defined by having the same unit mass value) but of dif-
ferent elemental composition (Table 2). Three examples 
involved multiple compounds with nominal masses of m/z 
316 (4 compounds), m/z 264 (3 compounds) and m/z 340 (3 
compounds). All isobaric cases were easily discriminated 
by their tR, and with the applied high-resolution MS, they 
were able to be differentiated according to their accurate 
mass values (Table 2). As depicted in Fig. 3, chlorpromazine 
and fluvoxamine (with the same nominal mass of m/z 319) 
result in tRs of 7.59 and 6.99 min, respectively. In addition, 
it was noted that all assumptions about specificity of iden-
tification are limited to only 113 targeted substances. How-
ever, there are possibilities of thousands other compounds or 
Table 2  Sets of isobaric 
compounds, having same unit 
mass value
Sets of 
isobaric com-
pounds
Compounds Elemental composition Exact mass [M + H]+ Ret. time (min)
1 6-Acetylmorphine C19H21NO4 328.1549 1.18
Loxapine C18H18ClN3O 328.1217 6.55
2 Benztropine C21H25NO 308.2014 7.33
Zolpidem C19H21N3O 308.1763 4.77
3 Bromazepam C14H10BrN3O 316.0086 6.16
Chlorprothixene C18H18ClNS 316.0927 7.74
Clonazepam C15H10ClN3O3 316.0489 7.65
Oxycodone C18H21NO4 316.1549 1.11
4 Chlorphenamine C16H19ClN2 275.1315 5.70
Ropivacaine C17H26N2O 275.2124 3.80
5 Chlorpromazine C17H19ClN2S 319.1036 7.59
Fluvoxamine C15H21F3N2O2 319.1633 6.99
6 Citalopram C20H21FN2O 325.1716 6.29
Quinine C20H24N2O2 325.1916 2.76
7 Desmethylvenlafaxine C16H25NO2 264.1963 2.62
Nortriptyline C19H21N 264.1752 7.05
Tramadol C15H25NO2 264.1964 2.02
8 Disopyramide C21H29N3O 340.2389 4.21
Perazine C20H25N3S 340.1847 6.86
Propoxyphene C22H29NO2 340.2277 7.11
9 Doxylamine C17H22N2O 271.1811 2.09
Nordiazepam C15H11ClN2O 271.0638 8.03
10 Flunitrazepam C16H12FN3O3 314.0941 8.04
Reboxetine C19H23NO3 314.1756 6.32
11 Fluoxetine C17H18F3NO 310.1419 7.52
Methadone C21H27NO 310.2171 7.20
12 Haloperidol C21H23ClFNO2 376.1479 6.54
Pipamperone C21H30FN3O2 376.2400 2.41
13 Mirtazepine C17H19N3 266.1657 3.98
Oxprenolol C15H23NO3 266.1756 4.82
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metabolites to be present including isomers (same elemental 
composition but different arrangement of atoms) which can-
not be distinguished by full scan mode of HRMS. 
Performance of the Method
Method performance was assessed regarding selectivity, 
specificity, linearity, limit of detection (LOD) and limit 
of quantification (LOQ) using TraceFinder 3.0 software. 
Selectivity is a crucial parameter for complex samples such 
as biological samples. In HRMS detection, accurate mass 
operation enhances selectivity and reduces interferences 
[25]. In some conditions, an increased window from 5 ppm 
to 10 ppm may be used to identify more compounds and 
obtain better results [29]. In this study, virtually all of the 
ions generated were monitored with almost zero background 
in the XICs when setting a narrow mass extraction window 
(5 ppm), illustrating good specificity of the method (see, 
Figs. 2 and 3).
Based on XIC ion data, peak areas were generated for all 
the compounds in standard mixtures of different concentra-
tions according to the software calculated values, to allow 
construction of calibration curves. Linearity was studied 
for different analytes based on a five-point concentration 
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Fig. 3  XICs of 2 isobaric compounds which have same nominal 
mass of m/z 319 a chlorpromazine (exact mass of 319.1036) eluted 
at retention time of 7.59  min and b fluvoxamine (exact mass of 
319.1633) eluted at retention time of 6.99 min
Table 3  The number of positive cases with concentration of drugs 
and metabolites detected (ng mL−1)
Drugs and metabolites Number of posi-
tive cases
Concentration range 
detected (ng mL−1)
Cotinine 21 0.5–920
Nortriptyline 11 51.6–440
Nicotine 14 0.6–36.9
Paracetamol 12 300–330
Oxycodone 10 0.6–49.1
Caffeine 10 270–1.2 × 104
Pethidine 7 1.3–1.4
Sotalol 5 19.5–1.0 × 103
Metoclopramide 6 23.9–430
Diazepam 6 7.1–260
Oxazepam 5 1.8–55.8
Nordiazepam 5 9.6–190
Midazolam 4 6.3–1.7 × 103
Levetiracetam 4 3.9 × 103 – 2.9 × 104
Reboxetine 4 0.6
Lidocaine 3 500–1.2 × 104
MDA 3 40.4–390
Clonazepam 2 3.5–5.1
Quetiapine 2 120–600
Doxylamine 2 47.8–100
Doxepin 2 0.9–200
Methadone 2 190–480
6-acetylmorphine 2 20.8–22.8
7-aminoclonazepam 2 10.9–280
Citalopram 2 190–560
Diltiazem 2 64.8–120
Levomepromazine 2 1.2
Pericyazine 2 2.6–4.4
Amphetamine 1 14.5
Hydroxyrisperidone 1 4.8
Bromazepam 1 0.7
Cocaine 1 1.9
Bupivacaine 1 610
Venlafaxine 1 270
Propranolol 1 2
Verapamil 1 980
Desmethylvenlafaxine 1 590
Ketamine 1 140
Tramadol 1 580
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calibration. Calibration curves were obtained with r2 val-
ues > 0.99 for most of the analytes (Table 1). By using 
TraceFinder data, analyte concentrations in real samples 
were established, according to the calibration curves and 
analyte peak areas.
The LOD was determined as the lowest concentration giv-
ing a signal–noise ratio that was at least threefold (S/N > 3), 
and LOQ as the lowest concentration of the calibration 
curve, giving a signal–noise ratio at least tenfold (S/N > 10). 
This method showed excellent sensitivity with low LODs 
obtained (Table 1). The lowest LODs were 0.02 ng mL−1, 
for chlorphenamine, hydroxyrisperidone, MDMA, nicotine, 
nortriptyline, zopiclone and zuclopenthixol.
Application of the Method
To evaluate the applicability of LC–Orbitrap MS with full 
scan operation, it was employed to screen for a broad range 
of drugs in 26 blind biological samples, provided by the 
VIFM, extracted as detailed in the Experimental section. 
A blank sample was analysed after each extract sample to 
check for possible carryover; no carryover was noted. The 
sample data were imported to TraceFinder software to match 
the sample information with that of the exact mass database 
of the standards. Although this study was provided with sus-
pected positive drug samples, the results confirmed that all 
of these forensic cases were indeed positive, with agreement 
of all positive drugs found according to a parallel LC–MS/
MS prior analysis; in addition, this study identified further 
positive drug hits attributed to its improved lower LOD and 
LOQ. Table 3 displays the number of positive cases, along 
with the average concentration of drugs detected, while the 
detailed information of each sample are shown in electronic 
supplementary material (Table S1). Cotinine is the most 
common compound found in 21 cases. In addition, some 
drugs were detected at concentrations below their LOQ val-
ues, but above their LOD values.
Of the 26 forensic cases, sample case no. 7 reported the 
highest number of basic drugs (17 drug compounds) in the 
sample, and a further four drugs detected at concentrations 
below the LOQ values (clozapine, doxepin, perazine and 
perphenazine). Figure 4 illustrates the XIC of methadone 
using full scan mode in standard solution and in posi-
tive sample case no. 7 with a retention time deviation of 
0.02 min. A comparison between the XIC of standard solu-
tions and the positive samples was conducted to reduce any 
potential for false positives in the screening results. The very 
clean XIC trace indicates that there were no interferences in 
the chromatogram at this mass accuracy; the method posi-
tively identified this compound in the biological matrix at 
trace level. Although the accurate mass XIC display gives 
a ‘clean’ result without interference, the full mass spec-
trum of the peak at the respective retention time can display 
other ions detected at that time should there be either other 
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drugs or chromatographic interferences overlapping the 
target drug. In addition, it should be noted that MDA was 
detected in three forensic samples (Table 3). Since MDA 
is the metabolite of MDMA, the absence of MDMA may 
indicate the possibility of false-positive identification.
Conclusion
The application of LC–Q-Orbitrap MS for analysis of 113 
targeted drugs in blood samples with high-performance 
separation in reversed-phase mode and high-resolution 
MS analysis has been demonstrated. HRMS screening 
produces high selectivity and specificity, based on the full 
scan exact mass measurement of [M + H]+ ions at a narrow 
mass extraction window. Since HRMS without confirma-
tion by MS/MS has a tendency to obtain false-positive 
identification, thus it is only suited for screening purposes. 
The exact mass of an analyte combined with retention time 
data facilitates the identification of each target component, 
with excellent mass accuracy. In general, isobaric com-
pounds were easily distinguished and identified by their 
different retention times, and accurate mass data. The reli-
able analysis of a broad range of drugs may be performed 
with acceptable low LODs obtained with little interference 
in the extracted ion chromatogram. The method allowed 
identification and quantification of target compounds at 
low levels. The results of this study represent a promising 
tool for large-scale screening and quantification, feasible 
for use in routine analysis.
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